A new study led by a University of Cincinnati researcher provides more clarity on how immunotherapy treatment for patients with cancer affects COVID-19 severity.
Duke Health researchers have identified a unique process within the environment of glioblastoma brain tumors that drives resistance to immune-boosting therapies and could be targeted to promote the effects of those drugs.
A large study by researchers at the American Cancer Society demonstrated that adult cancer survivors, particularly those diagnosed within five years and/or those who have a history of chemotherapy, have an increased risk for bone fractures, specifically pelvic and vertebral fractures, compared to older adults without cancer.
Research findings from the Johns Hopkins Kimmel Cancer Center show how higher viscosity, or resistance to flow, of the extracellular fluid that surrounds cells enables cancer cells to migrate more rapidly from a primary tumor to other sites in the body.
Researchers at University of California San Diego School of Medicine and the VA San Diego Healthcare System, with colleagues elsewhere, report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer.
Researchers at VCU Massey Cancer Center published study findings that establish rationale for the use of a class of drugs known as MDA-9 inhibitors as a potential treatment option for aggressive liver cancer.
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco has discovered the underlying cause of gender differences in treatment-associated myocarditis after immune checkpoint inhibitor treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.
Researchers at UT Southwestern reported in the journal Nature Cancer that Talzenna (talazoparib) successfully shrank the tumors of breast cancer patients with mutations in the PALB2 gene.
In a large analysis of prostate cancer patients treated internationally across 12 randomized trials, research from UCLA Jonsson Comprehensive Cancer Center suggests that it is almost universally optimal for men to receive androgen deprivation therapy during and after radiation therapy, rather than before and during RT.
Researchers from MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were presented Oct. 25 at the 2022 American Society for Radiation Oncology Annual Meeting.
